-
 GeT IN at CBAI
Get in @ CBAI before those cheap stock are not here any more.
-
 Cbai
If you do your DD on CBAI you will see this is an awesome opportunity to accumulate shares of a company doing everything right. They plan to grow there current $5M/yr revenue stream by chewing up smaller competitors now that they have the cash and a state of the art Stem Cell facilty. Currently trading at .0034. An OTCBB fulling reporting company. IMO. GLTA
"Cord Blood America, Inc. (OTC Bulletin Board: CBAI), one of the largest umbilical cord blood stem cell preservation companies focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today it has hired famed Immunologist Dr. Geoffrey John O'Neill as its new Laboratory Director and Brian Pockett as Vice President of Laboratory Operations".
-
15.63% increase today on 244+ Million shares. One of the biggest days for them this year. I think this one is getting all the pieces in place. Should be a mover after the first of the year if not before then. It's still a bargain right now but I don't think it'll last.
Cord Blood America CEO Discusses New State-of-the-Art State Laboratory in Fox News Television Interview
Wednesday 07/22/2009 12:59 PM ET - Pr Newswire
Cord Blood America, Inc. (OTC Bulletin Board: CBAI), one of the largest umbilical cord blood stem cell preservation companies (Cord Blood America CEO Discusses New State-of-the-Art State Laboratory in Fox News Television Interview | MyBlog) focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that its founder and CEO Matthew Schissler was featured on Monday in a television interview on KVVU Fox News Las Vegas, in which he discusses the 17,000 square foot facility in Las Vegas, Nevada that it recently leased to develop a state-of-the-art laboratory for the storage of multiple stem cell products including umbilical cord blood stem cells.
"Since we announced earlier this month that we had leased the Facility, there has been tremendous interest from parties in the Western United States in discussing opportunities to partner with the Company," said Mr. Schissler. "In addition to our current cord blood stem cell business, we are excited about having the capability to process and store multiple forms of stem cells, and expect to begin generating different revenue streams from the sale of these services in early 2010."
The entire interview is available at Cord Blood America CEO Discusses New State-of-the-Art State Laboratory in Fox News Television Interview | MyBlog.
-
SANTA MONICA, Calif. and LAS VEGAS, Aug. 11 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), one of the largest umbilical cord blood stem cell preservation companies (Cord Blood America News ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that work has begun at its new, 17,000 square foot facility in Las Vegas for conversion into a state-of-the-art laboratory for the storage of stem cells and for research and development.
"Our target for having a cord blood processing lab in operation, a testing lab, and a cryogenic storage area is the fourth quarter of 2009. This will complete Phase One of the construction. Currently architectural plans are completed and needed demolition of parts of the interior building is underway," said Matthew Schissler, CEO and founder of Cord Blood America.
"Phase Two will involve building out of the largest cryogenic facilities in the country, as well as a research laboratory, additional processing labs and a clean room," Mr. Schissler said. "Completion is expected in 2010."
Cord Blood America recently announced it is opening a state-of-the-art laboratory for the storage of multiple stem cell products, including umbilical cord blood stem cells, in Las Vegas. The lab will be used to process and store umbilical cord blood stem cells, to store other forms of stem cells such as stem cells from the peripheral blood stream and adipose tissues, and for research and product development.
Dr. Geoffrey John O'Neill, author or co-author of more than 75 publications about stem cells, and former Laboratory and Scientific/Medical Director for Cryo-Cell International Inc. in Florida, will serve as Laboratory Director. Brian Pockett, with more than 30 years professional experience in operations, business development, marketing, sales and financial and grant development, including serving as a consultant on global distribution, product development, commercialization, investment and intellectual properties for some of the largest companies in the U.S., is Vice President of Laboratory Operations.
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at Umbilical Cord Blood Banking, Storage, Stem Cell Bank Preservation Corcell. For investor information, visit Cord Blood America News.
Forward-Looking Statements
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as ``anticipate,'' ``believe,'' ``expect,'' ``future,'' ``intend,'' ``plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
-
CBAI News
Cord Blood America Says Balance Sheet Significantly Strengthened in 2009
Aug 17, 2009 5:00:00 AM
SANTA MONICA, Calif., Aug. 17 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (Cord Blood America News) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that its 10Q filing with the U.S. Securities & Exchange Commission for the second quarter of 2009 shows a significantly improved balance sheet.
At June 30, 2009, Cord Blood America's working capital had increased by almost $4 million compared to year-end 2008. This is a 90 percent improvement in only six months.
The Company also had a balance of $324,549 in cash, an important increase as Cord Blood America moves forward with organic growth and possible acquisitions.
Further the 10Q has a schedule detailing the repayment of $5 million in debt in the first half of the year, one of the pillars needed for the Company to succeed.
"While revenues were down, due to very difficult economic conditions, and a significant de-emphasis on our advertising business, we are confident we have built the strong foundation necessary for the growth our shareholders want," said Matthew Schissler, founder and CEO.
"In addition, we anticipated being cash flow positive this year. However one time charges in Q2 including the cost of capital for the $7.5M raised, and significant testing and auditing of our SOP's, coupled with the excellent opportunity to build one of the largest stem cell storage facilities in the country, delayed this in the short term. There were significant sunk costs in Q2 that couldn't be avoided. All measures were taken to strengthen CBAI for the long term."
Mr. Schissler concluded: "Once the stem cell storage and research and development lab in Las Vegas is completed, CBAI will immediately increase our gross margins, bringing us closer to cash flow positive."
The 10Q can be found in its entirety at U.S. Securities and Exchange Commission (Home Page).
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at Umbilical Cord Blood Banking, Storage, Stem Cell Bank Preservation Corcell. For investor information, visit Cord Blood America News.
Forward-Looking Statements
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate,'' "believe,'' "expect,'' "future,'' "intend,'' "plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
CONTACT:
Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com
SOURCE Cord Blood America, Inc.
----------------------------------------------
Paul Knopick of E & E Communications
+1-949-707-5365
pknopick@eandecommunications.com
for Cord Blood America
Inc.
-
Cord Blood (CBAI)
IMO. For people looking for a great investment. This stock is a steal right now. Imagine the following:
First of all, Matt (Cord Blood CEO) has never had the buying power he has now. He almost has a clean balance sheet and he has $7.5M of equity funding available whenever he needs it. The dilution will soon be over. They have the new Lab and got a great price for it, immediatly improving the gross profit. Say this shows up in the 1Q 2010 results. He is currently #4 of 20 competitors according to him. So he will either be trying to gobble up smaller companies or at least offering leasing services to those currently storing stem cells in other places, or just getting started like all these new stem cell banks popping up. They will for sure be cash flow positive by 1Q 2010. And as I posted earlier they will save 15+% of revenue once the collection patent expires March 2010. So I predict they will be profitable in 2Q 2010. Any positive EPS will guarantee this stock will reach at least 15 times multiple or at least $.10+ a share.
Now if you bought 10M shares today for about $30K, once they obtain a postivie EPS this stock will soar to at least 10 cents a share no doubt. With a $30K investment equalling 10M shares, at $.10 you become a millionare. I say no later than September 2010.
Other thoughts welcome.
GLTA
-
 Originally Posted by dmuse2
IMO. For people looking for a great investment. This stock is a steal right now. Imagine the following:
First of all, Matt (Cord Blood CEO) has never had the buying power he has now. He almost has a clean balance sheet and he has $7.5M of equity funding available whenever he needs it. The dilution will soon be over. They have the new Lab and got a great price for it, immediatly improving the gross profit. Say this shows up in the 1Q 2010 results. He is currently #4 of 20 competitors according to him. So he will either be trying to gobble up smaller companies or at least offering leasing services to those currently storing stem cells in other places, or just getting started like all these new stem cell banks popping up. They will for sure be cash flow positive by 1Q 2010. And as I posted earlier they will save 15+% of revenue once the collection patent expires March 2010. So I predict they will be profitable in 2Q 2010. Any positive EPS will guarantee this stock will reach at least 15 times multiple or at least $.10+ a share.
Now if you bought 10M shares today for about $30K, once they obtain a postivie EPS this stock will soar to at least 10 cents a share no doubt. With a $30K investment equalling 10M shares, at $.10 you become a millionare. I say no later than September 2010.
Other thoughts welcome.
GLTA
Ever since I bought (CBAI) about 12 months ago, it went far way down south, never to raise again.. I will buy few hundreds later, the stock are very cheap..
-
CBAI - Cord Blood
News this morning. This thing is going to be a rocketship IMO.
Cord Blood America Opens Las Vegas Cryogenic Laboratory; Consolidates Offices in Nevada
Cord Blood America Opens Las Vegas Cryogenic Laboratory; Consolidates Offices in Nevada
Sep. 30, 2009 (PR Newswire) --
LAS VEGAS, Sept. 30 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (Cord Blood America News ) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that it is opening its new Corporate headquarters and cryogenic research and storage laboratory in Las Vegas, as planned, the first week of October.
Matthew Schissler, founder and CEO, said the 17,000 square foot facility is perhaps the one of the largest cryogenic storage facility in the U.S. "Our goal is to ensure CBAI becomes one of the largest cryogenic storage companies in the world," Cord Blood America's founder said.
"The new facility will significantly reduce the cost of sales while increasing gross profits, because we no longer have to outsource the storage and because of its proximity to one of the nation's busiest airports," Mr. Schissler said.
"It allows us to expand our arsenal, storing other stem cells such as adipose tissue and peripheral blood stem cells. Also, we will explore wholesale storage contracts with other companies for a profit, as well as store other medical necessities including plasma or tissue. Having the new facility will move CBAI away from being strictly a business to consumer sales company of cord blood stem cell storage. CBAI will have the ability to offer multiple consumer storage products, while adding additional business- to-business revenue streams, with possibly an additional layer of research and development."
"We anticipate processing of stem cells in the new lab to commence sometime in the fourth quarter of 2009. We are confident that this new facility will assist Cord Blood America to become a giant in the cryogenic storage sector," Mr. Schissler said.
-
CBAI top end
Does anyone see CBAI getting in excess of .10 in the next few months. Have 450k @ .0075. Trying to decide if I take a little profit this month, or wait for a home run next year.
-
CBAI News
Corcell, a wholly owned sub of CBAI is now the preferred provider for Blue Cross which provides the insurance for most US unions. Big news.
Blue Cross And Blue Shield Association National Labor Office Selects CorCell ® and FutureScripts ® As Strategic Alliance Partners
|
Checking For Related Data... |
View Profile
View Forum Posts
Private Message
Reply With Quote
Posting Permissions
Bookmarks